Karuna Therapeutics Overview
- Founded
- 2009
- Status
- Public
- Employees
- 118
- Stock Symbol
- KRTX
- Share Price
- $99.35
- (As of Monday Closing)
Karuna Therapeutics General Information
Description
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.
Contact Information
Website
www.karunatx.com
Formerly Known As
Karuna Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 33 Arch Street
- Suite 3110
- Boston, MA 02110
- United States
+1 (857) 000-0000
Karuna Therapeutics Timeline
Karuna Therapeutics Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $99.35 | $98.90 | $93.77 - $161.98 | $2.95B | 29.8M | 205K | -$4.94 |
Karuna Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 3,389,802 | 3,389,802 | 2,381,267 | 1,798,416 |
| Revenue | 36,964 | 36,964 | 0 | 0 |
| EBITDA | (143,795) | (143,795) | (71,671) | (45,482) |
| Net Income | (143,805) | (143,805) | (68,554) | (43,957) |
| Total Assets | 527,671 | 527,671 | 347,625 | 393,024 |
| Total Debt | 7,503 | 7,503 | 2,685 | 208 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Karuna Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Karuna Therapeutics‘s full profile, request access.
Request a free trialKaruna Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore Karuna Therapeutics‘s full profile, request access.
Request a free trialKaruna Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address d
Drug Discovery
Boston, MA
118
As of 2021
00000
00000000000
00000
0000000
m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irur
0000 000000000
South San Francisco, CA
000
As of 0000
00000
000000 - 000
00000
00000000
is nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate veli
0000 000000000
Clarksville, MD
0
As of 0000
00.000
000000 0
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialKaruna Therapeutics Competitors (20)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alector | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 000000000000 | Venture Capital-Backed | Clarksville, MD | 0 | 00.000 | 000000 0 | |
| 0000000 | Venture Capital-Backed | Framingham, MA | 00 | 000.00 | 00000000000 | 000.00 |
| 0000000 | Venture Capital-Backed | Singapore, Singapore | 00 | 00000 | 00000 00000 | |
| 000000 0000 000000 | Corporation | New York, NY | 00 | 000.00 | 000000 - 000 | 000.00 |
Karuna Therapeutics Patents
Karuna Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210145804-A1 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | Pending | 18-Nov-2019 | 000000000 | |
| US-20210145810-A1 | Xanomeline derivatives and methods for treating neurological disorders | Pending | 15-Nov-2019 | 0000000000 | |
| AU-2020226870-A1 | Compounds and methods of deuterated xanomeline for treating neurological disorders | Pending | 22-Feb-2019 | 000000000 | |
| CA-3131128-A1 | Compounds and methods of deuterated xanomeline for treating neurological disorders | Pending | 22-Feb-2019 | 000000000 | |
| US-20210177762-A1 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | Pending | 28-Sep-2018 | A61K9/1652 |
Karuna Therapeutics Executive Team (7)
Karuna Therapeutics Board Members (18)
| Name | Representing | Role | Since |
|---|---|---|---|
| Atul Pande MD | Self | Board Member | 000 0000 |
| Christopher Coughlin | Self | Board Member | 000 0000 |
| Daphna Zohar | PureTech Health | Board Member | 000 0000 |
| David Wheadon MD | Self | Board Member | 000 0000 |
| Denice Torres | Self | Board Member | 000 0000 |
Karuna Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialKaruna Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Karuna Therapeutics‘s full profile, request access.
Request a free trial